New study reveals how long patients stay on secukinumab for skin and joint conditions

NCT ID NCT05155098

Completed Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study followed 127 adults with moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis who were already taking or starting secukinumab. Researchers observed them for two years to see how long they continued the medication and how their quality of life changed. The goal was to gather real-world data on treatment patterns and effectiveness outside of a controlled clinical trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: secukinumab
What this could lead to: If successful, this study could show how well secukinumab works in everyday practice, helping doctors and patients make more informed treatment decisions.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection or lifestyle. It does not test a new treatment or prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis Non-Radiographic Axial Spondyloarthritis psoriasis psoriatic arthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANKYLOSING SPONDYLITIS MODERATE TO SEVERE PLAQUE PSORIASIS NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS PSORIATIC ARTHRITIS

Contacts and locations

Locations

Novartis Investigative Site

Songkhla, Hat Yai, 90110, Thailand
Novartis Investigative Site

Muang, Thailand, 12120, Thailand
Novartis Investigative Site

Khon Kaen, THA, 40002, Thailand
Novartis Investigative Site

Bangkok, 10300, Thailand
Novartis Investigative Site

Bangkok, 10330, Thailand
Novartis Investigative Site

Bangkok, 10400, Thailand
Novartis Investigative Site

Bangkok, 10700, Thailand
Novartis Investigative Site

Chiang Mai, 50200, Thailand
Novartis Investigative Site

Kaen, 40000, Thailand
Novartis Investigative Site

Nakhon Ratchasima, 30000, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.